The long-term view of regenerative medicine therapies predicts an increased need for expansion solutions that ease scalability, utilize animal origin-free materials and are compatible with limited downstream processing steps. As more cell therapeutics progress through clinical testing, current <i>in vitro</i> culture methods are proving cumbersome to scale and lack robustness. Moreover, high quality animal origin-free reagents and downstream processing devices support the future implementation of production solutions that will be required following clinical success. Here, we describe the implementation of single use bioreactors and high quality media for expansion of cell therapies. We include examples from allogeneic mesenchymal stem cells, autologous T cells and induced pluripotent stem cells. The presentation will include case studies that demonstrate process improvements when using qualified media, serum alternatives, bioreactors and downstream purification technologies. Additionally, we will highlight the inclusion of process control strategies that further increase the efficiency of cell therapy production. Start to finish solutions for expansion and harvest are key enabling technologies for success in commercializing cell therapies.

Solutions for robust cell therapy production

253rd National Meeting (2017)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.